Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms

Delshad, Sean; Almario, Christopher V.; Chey, William D.; Spiegel, Brennan

doi:10.1053/j.gastro.2019.12.014

Cited by 166 publications

(131 citation statements)

References 45 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…In community studies, persistent symptoms are observed in 40-55% of daily PPI users. 61,62 PPIrefractory GERD represents a heterogeneous group of patients and a significant proportion of patients is suffering from non-GERD-related conditions. Nonreflux-related and functional esophageal symptoms (such as belching, rumination, and globus) are often falsely interpreted as reflux symptoms.…”

Section: Ppi-refractory Gerd Patients: How To Deal With Them?mentioning

confidence: 99%

Pharmacologic treatment of GERD: Where we are now, and where are we going?

Scarpignato

Hongo

et al. 2020

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

The introduction of acid inhibition in clinical practice has revolutionized the management of acid-related diseases, leading to the virtual abolition of elective surgery for ulcer disease and relegating antireflux surgery to patients with gastroesophageal reflux disease (GERD) not adequately managed by medical therapy. Proton pump inhibitors (PPIs) are the antisecretory drugs of choice for the treatment of reflux disease. However, these drugs still leave some unmet clinical needs in GERD. PPI-refractoriness is common, and persistent symptoms are observed in up to 40-55% of daily PPI users. Potassium-competitive acid blockers (P-CABs) clearly overcome many of the drawbacks and limitations of PPIs, achieving rapid, potent, and prolonged acid suppression, offering the opportunity to address many of the unmet needs. In recent years, it has been increasingly recognized that impaired mucosal integrity is involved in the pathogenesis of GERD. As a consequence, esophageal mucosal protection has emerged as a new, promising therapeutic avenue. When P-CABS are used as add-on medications to standard treatment, a growing body of evidence suggests a significant additional benefit, especially in the relief of symptoms not responding to PPI therapy. On the contrary, reflux inhibitors are considered a promise unfulfilled, and prokinetic agents should only be used on a case-by-case basis.

show abstract

Section: Ppi-refractory Gerd Patients: How To Deal With Them?mentioning

confidence: 99%

Pharmacologic treatment of GERD: Where we are now, and where are we going?

Scarpignato

Hongo

et al. 2020

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

show abstract

“…1,2 The application of genomics, epigenetics, and pharmacogenomics holds much promise in the field; however, the variants of genes frequently mutated and the heterogenicity of FBDs will challenge the application of human genomics to the field. 3,4 The prevalence of FBDs remains unclear because there is great variance in both the populations studied and the survey instruments used. 5,6 The Rome criteria are currently…”

Section: Are the Rome Criteria A Sound Standard For Gastrointestinal mentioning

confidence: 99%

“…1,2 However, time trends in diet, obesity, and the racial and ethnic composition of the US population may have resulted in changes in the current prevalence of GERD. The investigators in this study 3 obtained information from a large number of individuals across the United States using a mobile application designed to elicit eight major gastrointestinal symptom categories, including (1) heartburn, acid reflux, or gastroesophageal reflux, (2) abdominal pain, (3) bloating/gas, (4) constipation, (5) diarrhea, (6) disrupted swallowing, (7) fecal incontinence, and (8) nausea and vomiting. Focusing only on symptoms of GERD, they found that 31% of respondents experienced heartburn, acid reflux or gastroesophageal reflux within the week before being surveyed.…”

mentioning

confidence: 99%

What’s App with GERD?

Inadomi

2020

Gastroenterology

View full text Add to dashboard Cite

“…Like obesity, GERD was also recently reported to affect approximately a third of American adults, and its prevalence is steadily growing. 5 GERD is defined as the reflux of stomach contents into the esophagus, often resulting in bothersome symptoms and complications. Reported symptoms are diverse and include retrosternal burning (most common), regurgitation, dysphagia, chest pain, hypersalivation, globus sensation, and nausea.…”

Section: Introductionmentioning

confidence: 99%